Reviewing Mannatech (NASDAQ:MTEX) and Crinetics Pharmaceuticals (NASDAQ:CRNX)

Mannatech (NASDAQ:MTEX) and Crinetics Pharmaceuticals (NASDAQ:CRNX) are both medical companies, but which is the better stock? We will contrast the two companies based on the strength of their analyst recommendations, institutional ownership, valuation, profitability, risk, earnings and dividends.

Volatility and Risk

Mannatech has a beta of 0.72, indicating that its share price is 28% less volatile than the S&P 500. Comparatively, Crinetics Pharmaceuticals has a beta of 0.24, indicating that its share price is 76% less volatile than the S&P 500.

Institutional & Insider Ownership

13.0% of Mannatech shares are held by institutional investors. Comparatively, 98.5% of Crinetics Pharmaceuticals shares are held by institutional investors. 41.5% of Mannatech shares are held by insiders. Comparatively, 3.8% of Crinetics Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Analyst Recommendations

This is a breakdown of recent ratings and recommmendations for Mannatech and Crinetics Pharmaceuticals, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Mannatech	1	0	0	0	1.00
Crinetics Pharmaceuticals	1	0	8	1	2.90

Crinetics Pharmaceuticals has a consensus price target of $76.13, suggesting a potential upside of 131.24%. Given Crinetics Pharmaceuticals’ stronger consensus rating and higher possible upside, analysts clearly believe Crinetics Pharmaceuticals is more favorable than Mannatech.

Profitability

This table compares Mannatech and Crinetics Pharmaceuticals’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Mannatech	-11.97%	-2,383.34%	-40.24%
Crinetics Pharmaceuticals	-2,747.18%	-43.96%	-39.61%

Earnings and Valuation

This table compares Mannatech and Crinetics Pharmaceuticals”s revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Mannatech	$108.04 million	0.10	-$15.21 million	($6.71)	-0.85
Crinetics Pharmaceuticals	$7.70 million	450.79	-$465.32 million	($5.13)	-6.42

Mannatech has higher revenue and earnings than Crinetics Pharmaceuticals. Crinetics Pharmaceuticals is trading at a lower price-to-earnings ratio than Mannatech, indicating that it is currently the more affordable of the two stocks.

Summary

Crinetics Pharmaceuticals beats Mannatech on 9 of the 15 factors compared between the two stocks.

About Mannatech

Mannatech, Incorporated operates as a health and wellness company in the Americas, Europe, the Middle East, Africa, and the Asia-Pacific. The company develops, markets, and sells nutritional supplements; topical and skin care, and anti-aging products; and weight-management and fitness products. It primarily sells its products directly, as well as through e-commerce and network marketing channels. Mannatech, Incorporated was incorporated in 1993 and is headquartered in Flower Mound, Texas.

About Crinetics Pharmaceuticals

Crinetics Pharmaceuticals, Inc., a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors. The company's lead product candidate is paltusotine, an oral selective nonpeptide somatostatin receptor type 2 agonist, which is in Phase 3 trial for the treatment of acromegaly; and Phase 2 trial for treating carcinoid syndrome associated with neuroendocrine tumors. It is also developing CRN04894, an investigational oral nonpeptide product candidate to antagonize the adrenocorticotrophic hormone (ACTH) receptor that has completed a Phase 1 study for the treatment of diseases caused by excess ACTH, including congenital adrenal hyperplasia and Cushing's disease. In addition, the company is developing antagonists of the parathyroid hormone (PTH) receptor for the treatment of primary hyperparathyroidism and humoral hypercalcemia of malignancy, and other diseases of excess PTH; identified investigational orally available somatostatin receptor type 3 targeted nonpeptide agonists for the treatment of autosomal dominant polycystic kidney disease; and developing thyroid-stimulating hormone receptor antagonists for the treatment of graves' disease and thyroid eye disease, as well as Oral GLP-1 and GIP nonpeptides for the treatment of diabetes and obesity. Crinetics Pharmaceuticals, Inc. was incorporated in 2008 and is headquartered in San Diego, California.